Comparison of efficacy and safety between TIcagrelor and clopidogrel in Chinese patients with acute coronary syndrome (COSTIC study).

Int J Cardiol Heart Vasc · 2026 · PMC12818067 · PMID 41567128

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an observed trendno p-value reported

However, an observed trend suggested a numerically higher incidence of I endpoint in the clopidogrel group at 180 days (2.8 % for clopidogrel group vs. 2.1 % for ticagrelor group; HR, 1.33; 95 % CI, 0.98–1.80; P = 0.07).

also in 257 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.